{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022013","form_type":"8-K/A","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.672078+00:00","generated_at":"2026-05-16T20:52:20.134772+00:00","sec_items":["7.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Elite Pharmaceuticals Corrects Conference Call Date for Q2 Fiscal 2026 Results","bullets":["Q2 FY2026 financial results (ended Sept 30, 2025) to be released on Friday, November 14, 2025.","Conference call scheduled for Monday, November 17, 2025 at 11:30 AM EST to discuss results and provide update.","Form 8-K/A amends prior filing solely to correct the conference call date in Item 7.01.","Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international); conference ID 98840.","Stockholder questions due by 5:00 PM EST on Nov 13 (general) and 7:00 PM EST on Nov 14 (financial)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022013","json":"https://secwatch.observer/filing/0001493152-25-022013.json","markdown":"https://secwatch.observer/filing/0001493152-25-022013.md","text":"https://secwatch.observer/filing/0001493152-25-022013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315225022013/0001493152-25-022013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315225022013/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T20:52:20.134772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}